Live cell immunization is a powerful technique for generating mAbs, particularly when targeting membrane proteins or protein complexes that are difficult to purify. It is especially effective against intractable targets, including conformational epitopes, complex post-translational modifications (PTMs), aberrant isoforms, and multimeric complexes. However, conventional live cell immunization methods are labor-intensive and often carry a high risk of non-specific antibody generation. 

Our Live Cell Immunization and High-Throughput Screening (LCI-HTS) platform overcomes these limitations, enabling the discovery of First-in-Class (FIC) antibodies against challenging and previously undruggable receptors. By incorporating a proprietary counter-screening technology, we ensure that the antibodies generated are highly specific, selectively binding to novel conformational epitopes that are overexpressed in cancer cells but minimally or not expressed in normal tissues. This opens new avenues for targeted therapies in areas of high unmet medical need.